AIM ImmunoTech AIM

Jump To Section

    $

    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    .
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    +$0.00 (+1.71%)Past DayToday's Volume:
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    ,
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0
    9
    8
    7
    6
    5
    4
    3
    2
    1
    0
    0

    Relative Strength Index (RSI)

    - The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

    - The RSI is calculated using the following formula:

    RSI = 100 - (100 / (1 + RS))

    Where RS is the ratio of the average gains to the average losses over a specified period.

    - The default time period used is 14 days.

    - RSI values range between 0 and 100.

    RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

    RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

    RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

    About

    Business overview of AIM ImmunoTech (AIM)
    AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

    Key Insights

    Critical company metrics and information

    • Latest Closing Price

      $0.133

    • Market Cap

      $9.14 Million

    • Price-Earnings Ratio

      -2.22

    • Total Outstanding Shares

      68.75 Million Shares

    • Total Employees

      28

    • Dividend

      No dividend

    • IPO Date

      November 2, 1995

    • SIC Description

      Biological Products, (no Disgnostic Substances)

    • Primary Exchange

      American Stock Exchange

    • Type

      Common Stock

    • Headquarters

      2117 sw highway 484, Ocala, FL, 32801

    • Homepage

      https://www.aimimmuno.com

    Historical Stock Splits

    If you bought 528 shares of AIM before August 29, 2016, you'd have 1 share today.
    Execution DateSplit Amount
    June 11, 20191-for-44 (Reverse Split)
    August 29, 20161-for-12 (Reverse Split)

    Cash Flow Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Net Cash Flow From Financing Activities, Continuing$137,000
    Net Cash Flow, Continuing$-2.64 Million
    Net Cash Flow From Investing Activities, Continuing$334,000
    Net Cash Flow From Operating Activities, Continuing$-3.11 Million
    Net Cash Flow From Financing Activities$137,000
    Net Cash Flow From Investing Activities$334,000

    Income Statement

    July 1, 2024 to September 30, 2024
    MetricValue
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0
    Net Income/Loss Attributable To Parent$-3.70 Million
    Other Operating Expenses$3.09 Million
    Diluted Earnings Per Share$-0.06
    Income/Loss From Continuing Operations After Tax$-3.70 Million
    Diluted Average Shares$57.68 Million

    Comprehensive Income

    July 1, 2024 to September 30, 2024
    MetricValue
    Comprehensive Income/Loss$-3.70 Million
    Other Comprehensive Income/Loss$-3.70 Million
    Comprehensive Income/Loss Attributable To Noncontrolling Interest$0
    Comprehensive Income/Loss Attributable To Parent$-3.70 Million

    Balance Sheet

    July 1, 2024 to September 30, 2024
    MetricValue
    Noncurrent Assets$6.02 Million
    Equity$2.91 Million
    Current Liabilities$10.10 Million
    Accounts Payable$6.26 Million
    Liabilities$10.68 Million
    Assets$13.59 Million

    Historical Dividends

    Announcement DatePayment DateRecord DateAmountFrequency
    No historical dividends

    Recent Headlines From The Web

    Latest news, press releases, and media coverage about AIM from trusted financial sources
      Boost your savings and earn 4.15% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
      All TickersEarnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

      â“’ 2025 Financhle. All Rights Reserved.